- Home
- EXEL vs ARWR Comparison
EXEL vs ARWR Comparison
Compare EXEL & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXEL | ARWR |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 9.6B |
| IPO Year | 2000 | 1993 |
Fundamental Metrics
Financial Performance| Metric | EXEL | ARWR |
|---|---|---|
| Price | $41.94 | $64.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 24 | 10 |
| Target Price | $45.18 | ★ $63.70 |
| AVG Volume (30 Days) | 2.6M | ★ 3.4M |
| Earning Date | 11-04-2025 | 11-25-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.55 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,288,218,000.00 | $829,448,000.00 |
| Revenue This Year | $9.84 | N/A |
| Revenue Next Year | $11.92 | N/A |
| P/E Ratio | $17.50 | ★ N/A |
| Revenue Growth | 9.93 | ★ 23258.15 |
| 52 Week Low | $31.90 | $9.57 |
| 52 Week High | $49.62 | $72.36 |
Technical Indicators
Market Signals| Indicator | EXEL | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 62.85 |
| Support Level | $40.83 | $59.51 |
| Resistance Level | $42.09 | $72.36 |
| Average True Range (ATR) | 1.05 | 4.67 |
| MACD | -0.32 | -0.11 |
| Stochastic Oscillator | 30.00 | 59.17 |
Price Performance
Historical ComparisonAbout EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.